DIRS.INFO The most relevant business & tech news

☆ US Government Sends Initial Offers for Medicare Drug Price Cuts
▼ + stars: | 2024-02-01 | by ( Feb. | At A.M. | ) www.usnews.com time to read: +1 min

(Reuters) - The Biden administration is sending drugmakers opening offers for the U.S. Medicare program's first ever price negotiations on Thursday, the White House said in a statement. President Joe Biden's signature Inflation Reduction Act (IRA) allows Medicare, which covers 66 million Americans mostly aged 65 and older, to negotiate prices for some of its most costly drugs. The initial offers have been sent to manufacturers of 10 high-cost medicines, which include Bristol Myers Squibb and Pfizer's blood thinner Eliquis, Merck & Co's diabetes drug Januvia and Johnson & Johnson's blood thinner Xarelto. The HHS and White House did not disclose details on the offers. (Reporting by Urvi Dugar and Sriparna Roy in Bengaluru; Editing by Toby Chopra and Sriraj Kalluvila)

Persons: Biden, Medicare program's, Joe Biden's, Januvia, Johnson, Urvi Dugar, Sriparna Roy, Toby Chopra, Sriraj Organizations: Reuters, U.S, Medicare, U.S . Department of Health, Human Services, Bristol Myers Squibb, Merck, HHS, White Locations: Bengaluru

☆ Eli Lilly extends tender offer to buy Point Biopharma after low participation
▼ + stars: | 2023-11-17 | by ( ) www.reuters.com time to read: +1 min

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo Acquire Licensing RightsNov 17 (Reuters) - Eli Lilly (LLY.N) on Friday extended the deadline for Point Biopharma Global (PNT.O) shareholders by about two weeks to Dec. 1 to sell their stock, due to low participation. In October, Lilly agreed to acquire Point Biopharma in an all-cash deal valued at $1.4 billion to gain access to its experimental therapies that enable precise targeting of cancer. Lilly, which has offered to buy Point Biopharma shares at $12.50 a piece and has all regulatory approvals for the deal, said the price will remain the same during the extended period. The tender offer has been extended in order for the companies to satisfy the minimum tender condition.

Persons: Eli Lilly, Mike Segar, Lilly, Mounjaro, Sriparna Roy, Shinjini Organizations: Company, REUTERS, Biopharma, Thomson Locations: Branchburg , New Jersey, Bengaluru

☆ Lilly extends tender offer to acquire Point Biopharma to Dec 1
▼ + stars: | 2023-11-17 | by ( ) www.reuters.com time to read: 1 min

Persons: Eli Lilly, Mike Segar, LLY.N, Lilly, Sriparna Roy Organizations: Company, REUTERS, Thomson Locations: Branchburg , New Jersey, Bengaluru

☆ Aclaris shares plummet on terminating development of rheumatoid arthritis drug
▼ + stars: | 2023-11-13 | by ( ) www.reuters.com time to read: +1 min

Companies Aclaris Therapeutics Inc FollowNov 13 (Reuters) - Aclaris Therapeutics (ACRS.O) on Monday said it would stop development of its rheumatoid arthritis treatment after it failed in a mid-stage trial, sending its shares plunging 84% before the bell. The trial tested two doses of the drug, zunsemetinib, along with anti-rheumatic drug methotrexate compared to placebo and methotrexate in patients with moderate to severe rheumatoid arthritis who have inadequate response to methotrexate alone. There was no notable differentiation between zunsemetinib and placebo across any measures of efficacy at 12 weeks, the company said. The company will also be halting enrollment in an ongoing mid-stage trial studying the drug in psoriatic arthritis. The drug developer said it is also studying its drug ATI-1777 in patients with moderate to severe atopic dermatitis which is currently in mid-stage trial.

Persons: Sriparna Roy, Maju Samuel Organizations: Aclaris Therapeutics, ATI, Thomson Locations: Bengaluru

Nov 7 (Reuters) - The number of newborns with syphilis in the United States surged more than 10-fold in the last decade, the U.S. Centers for Disease Control and Prevention (CDC) reported on Tuesday. The agency said 3,761 cases were recorded in 2022, the highest in over 30 years, up from 334 cases in 2012. The 2022 cases included 231 stillbirths and 51 infant deaths. Congenital syphilis occurs when a mother with syphilis passes the infection to her baby during pregnancy. The CDC recommends screening for syphilis at the first prenatal care visit to reduce perinatal transmission.

Persons: Laura Bachmann, Bachmann, Sriparna Roy, Nancy Lapid Organizations: U.S . Centers for Disease Control, Prevention, CDC's, CDC, Thomson Locations: United, Bengaluru

☆ FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study
▼ + stars: | 2023-10-31 | by ( ) www.reuters.com time to read: +2 min

[1/2] A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston, Massachusetts, U.S., October 23, 2019. REUTERS/Brian Snyder/File Photo Acquire Licensing RightsOct 31 (Reuters) - A panel of advisers to the U.S. health regulator said on Tuesday Vertex Pharmaceuticals (VRTX.O) and CRISPR Therapeutics (CRSP.BN) could assess potential safety risks of their sickle cell disease gene therapy after approval. If the therapy is approved, Vertex has proposed a 15-year follow up of patients to evaluate the safety outcomes of the therapy. Patients who were treated with the therapy were free from severe vaso-occlusive crisis for 12 months from the infusion of exa-cel. "It was made pretty clear that any theoretical off-target editing concerns do not outweigh the benefits of drug approval," said Salim Syed, analyst at Mizuho.

Persons: Brian Snyder, Scot Wolfe, Salim Syed, Sriparna Roy, Krishna Chandra Organizations: Vertex Pharmaceuticals, REUTERS, CRISPR Therapeutics, Staff, U.S . Food, Drug Administration, UMass Chan Medical, Analysts, FDA, Mizuho, Thomson Locations: Boston , Massachusetts, U.S, Bengaluru

☆ Bristol Myers says it needs another year to hit target for new drugs
▼ + stars: | 2023-10-26 | by ( Michael Erman | ) www.reuters.com time to read: +2 min

Bristol Myers reported that it earned $4.1 billion, or $2 per share, in the third quarter, down from $4.3 billion, or $1.99 a share, a year earlier. Analysts, on average, had expected earnings per share of $1.76. It now expects earnings per share in the range of $7.50 to $7.65, up from its previous target of $7.35 to $7.65. Chief Operating Officer Chris Boerner is expected to become chief executive of Bristol Myers next month, replacing current CEO Giovanni Caforio. Earlier in October, BMS agreed to buy cancer drugmaker Mirati Therapeutics (MRTX.O) for up to $5.8 billion, in an attempt to diversify its oncology business.

Persons: David Elkins, Bristol Myers, Chris Boerner, Giovanni Caforio, Michael Erman, Sriparna Roy, Leslie Adler Organizations: Bristol Myers Squibb, BMS, Bristol, Therapeutics, Thomson Locations: The New Jersey

The logo of Johnson & Johnson is seen on a Brussels' office of the company in Diegem, Belgium September 21, 2023. J&J raised its annual profit forecast, helped by strong sales from its pharmaceutical business, and shares of the U.S. healthcare conglomerate were off about 1%. Excluding its consumer health unit, J&J now expects 2023 adjusted profit of $10.07 to $10.13 per share, up from its previous view of $10.00 to $10.10. Sales at J&J's medical device unit came in at $7.46 billion, shy of Wall Street estimates of $7.58 billion. J&J finalized the biggest shake-up in its 137-year history in August with the spinoff, but retained a 9.5% stake in its iconic consumer health business.

Persons: Johnson, Yves Herman, J, Vamil Divan, Joseph Wolk, Ozempic, Wolk, Bhanvi Satija, Sriparna Roy, Patrick Wingrove, Shounak Dasgupta, Bill Berkrot Organizations: Johnson, REUTERS, Guggenheim Partners, Vamil, Reuters Graphics, J, Thomson, &' $, & $, & $ Locations: Brussels, Diegem, Belgium, Bengaluru, New York

The logo of Johnson & Johnson is seen on a Brussels' office of the company in Diegem, Belgium September 21, 2023. Investors are focused on how J&J, now a standalone pharmaceutical and medical devices company, will reach its goal of $57 billion in drug sales by 2025. Johnson & Johnson recorded a $21-billion gain in the third quarter from the spin-off of its consumer health unit. Stelara, J&J's top-selling anti-inflammatory drug, brought in sales of $2.86 billion in the quarter, above LSEG estimates of $2.61 billion. Excluding its consumer health unit, J&J now expects 2023 adjusted profit of $10.07 to $10.13 per share, compared with its previous outlook of $10.00 to $10.10 per share.

Persons: Johnson, Yves Herman, MedTech, Cantor Fitzgerald, Louise Chen, Stelara, Joseph Wolk, Wolk, J, Bhanvi Satija, Sriparna Roy, Patrick Wingrove, Shounak Dasgupta Organizations: Johnson, REUTERS, Innovative Medicine, Reuters, Thomson, & $, & $ Locations: Brussels, Diegem, Belgium, Stelara, U.S, United States, Bengaluru, New York

☆ Drug retailer Rite Aid files for bankruptcy, gets $3.45 bln commitment
▼ + stars: | 2023-10-16 | by ( ) www.reuters.com time to read: +2 min

A woman shops inside a Rite Aid store underneath a DeepCam security camera in New York City, New York, U.S., June 25, 2020. The bankruptcy process will allow Rite Aid to resolve litigation claims in an "equitable manner", the company said. Rite Aid has appointed Jeffrey Stein as its new CEO and chief restructuring officer, replacing interim CEO Elizabeth Burr. Rite Aid has also reached an in-principle agreement with some of its senior secured noteholders that would significantly reduce its debt. MedImpact will serve as the 'stalking horse bidder' in a court-supervised sale process, Rite Aid said.

Persons: Lucas Jackson, Jeffrey Stein, Elizabeth Burr, Stein, Burr, noteholders, Abinaya Vijayaraghavan, Mariam Sunny, Sriparna Roy, Shweta Agarwal, Pooja Desai Organizations: REUTERS, Rite Aid Corp, U.S, Aid, Walgreens Boots Alliance, CVS Health, MedImpact Healthcare Systems, Solutions, Rite Aid, Bankruptcy, District of, Thomson Locations: New York City , New York, U.S, District of New Jersey, Bengaluru

☆ Pfizer slashes revenue forecast on lower COVID sales, will cut costs
▼ + stars: | 2023-10-13 | by ( Michael Erman | ) www.reuters.com time to read: +3 min

Pfizer and rivals have begun selling an updated COVID vaccine for this fall. The drugmaker said it now expects 2023 revenue of between $58 billion and $61 billion, down from its prior forecast of $67 billion to $70 billion. It had previously expected Paxlovid revenue of about $8 billion for the year. Pfizer also cut full-year revenue expectations for the COVID vaccine by about $2 billion due to lower-than-expected vaccination rates. Pfizer said its non-COVID products remain on track to achieve 6% to 8% revenue growth year over year in 2023.

Persons: Albert Boura, Michael Erman, Sriparna Roy, Bill Berkrot, Rod Nickel Organizations: Pfizer, U.S ., Strategic, Thomson Locations: York, New Jersey, Bengaluru

☆ Illumina to divest Grail within a year if it does not win challenge in EU court
▼ + stars: | 2023-10-13 | by ( ) www.reuters.com time to read: +2 min

Companies Grail Inc FollowIllumina Inc FollowOct 13 (Reuters) - Illumina (ILMN.O) said on Friday it would divest cancer test maker Grail (GRAL.O) in 12 months, according to the terms of the European Commission's order, if the life sciences company does not win its challenge in court. EU antitrust regulators on Thursday ordered Illumina to divest Grail, after it completed the deal before securing their approval. The San Diego-based genetic testing company last year challenged the EU watchdog saying it does not have jurisdiction over the acquisition of Grail. But if it is not successful with either its ECJ jurisdictional appeal or in a final decision of the U.S. Fifth Circuit Court of Appeals, Illumina will divest Grail. Illumina had in June appealed against the order by the Federal Trade Commission, which enforces antitrust law in the U.S., to divest Grail.

Persons: Illumina, it's, Sriparna Roy, Shilpi Majumdar Organizations: Illumina, European Court of Justice, U.S, Fifth, Appeals, Federal Trade Commission, Thomson Locations: San Diego, U.S, Bengaluru

☆ Novo Nordisk stops Ozempic kidney trial after early signs of success
▼ + stars: | 2023-10-10 | by ( Patrick Wingrove | ) www.reuters.com time to read: +2 min

Pens for the diabetes drug Ozempic sit on a production line to be packaged at Danish drugmaker Novo Nordisk's site in Hillerod, Denmark, September 26, 2023. Novo said the trial would be halted almost a year early based on a recommendation from the independent data monitoring board overseeing the study. Independent monitors can recommend stopping a trial early if there is clear evidence that a drug was going to succeed or fail based on interim analyses. Semaglutide is also the active ingredient in Novo Nordisk's powerful weight-loss drug Wegovy. Novo's success has also created an economic boom for Denmark, according to Danish economists, analysts, and executives at the Novo Nordisk Foundation.

Persons: Tom Little, Novo, Danish drugmaker, Wegovy, Emily Field, Patrick Wingrove, Sriparna Roy, Bill Berkrot Organizations: REUTERS, Novo Nordisk, Barclays, Novo Nordisk Foundation, Thomson Locations: Hillerod, Denmark, Danish, New York, Bengaluru

☆ Kaiser healthcare unions say weeklong strike possible early next month
▼ + stars: | 2023-10-09 | by ( Steve Gorman | ) www.reuters.com time to read: +3 min

[1/2] Healthcare workers strike in front of Kaiser Permanente Los Angeles Medical Center, as more than 75,000 Kaiser Permanente healthcare workers go on strike from October 4 to 7 across the United States, in Los Angeles, California, U.S. October 4, 2023. The Coalition of Kaiser Permanente Unions said on Monday it has served the company notice that a weeklong "follow-up strike is possible" starting Nov. 1 unless the two sides come to a settlement beforehand. The company did not have an immediate response to the unions' latest strike deadline. The strike, which ran for three days, marked the largest work stoppage to date in the healthcare sector. Kaiser said it kept its hospitals and emergency departments open during the walkout, staffed by doctors, managers and "contingency workers."

Persons: Julie Su, Su, Kaiser, Steve Gorman, Sriparna Roy, Caroline Humer, Shinjini Ganguli, Matthew Lewis Organizations: Healthcare, Kaiser Permanente Los Angeles Medical Center, Permanente, REUTERS, Kaiser Permanente, Coalition, Kaiser Permanente Unions, Union, Kaiser, District of Columbia, Thomson Locations: United States, Los Angeles , California, U.S, Kaiser, California, California , Oregon, Washington, , Colorado, Virginia, Seattle, Los Angeles, Bengaluru

☆ Amgen completes $27.8 bln Horizon Therapeutics deal
▼ + stars: | 2023-10-06 | by ( ) www.reuters.com time to read: +1 min

An Amgen sign is seen at the company's office in South San Francisco, California in this October 21, 2013 photo. Amgen, which has gained Horizon's two key products Tepezza and Krystexxa, said it will provide an updated annual forecast during its third-quarter earnings call. RBC Capital Markets analyst Gregory Renza expects Amgen's updated forecast to weave in revenue from Horizon's drugs, which could partially offset the company's "maturing product line". Tepezza could be a "core driver" for Amgen, Renza said, adding that the drug can bring in $3.9 billion in peak sales. Reporting by Mariam Sunny and Sriparna Roy in Bengaluru; Editing by Anil D'Silva and Sherry Jacob-PhillipsOur Standards: The Thomson Reuters Trust Principles.

Persons: Robert Galbraith, Gregory Renza, Renza, Mariam Sunny, Sriparna Roy, Anil D'Silva, Sherry Jacob, Phillips Organizations: Horizon Therapeutics, U.S . Federal Trade Commission, FTC, RBC Capital Markets, Thomson Locations: South San Francisco , California, Bengaluru

☆ Insulet CFO to step down, join 3M's healthcare business
▼ + stars: | 2023-10-03 | by ( ) www.reuters.com time to read: +1 min

The company has been contracted by the U.S. government to produce extra masks in response to the country's novel coronavirus outbreak. REUTERS/Nicholas Pfosi/File Photo Acquire Licensing RightsCompanies Insulet Corp Follow3M Co FollowOct 3 (Reuters) - Insulet Corp (PODD.O) said on Tuesday Wayde McMillan would step down as the medical device maker's chief financial officer, effective Oct. 20, to join 3M's (MMM.N) healthcare business. McMillan will join 3M as the financial chief of its unit, which the U.S. industrial conglomerate plans to spin off into a listed company. Insulet on Tuesday also reaffirmed its annual forecast for sales of its insulin pumps and total revenue. Insulet's accounting chief, Lauren Budden, will assume the additional responsibilities of interim CFO until a permanent successor is appointed, the medical device maker said.

Persons: Nicholas Pfosi, Wayde McMillan, McMillan, Insulet, Lauren Budden, Sriparna Roy, Shilpi Majumdar, Maju Samuel Organizations: U.S, REUTERS, Insulet, 3M, Thomson Locations: Maplewood , Minnesota, U.S, Bengaluru

☆ WHO says no new cases of Nipah virus detected since Sept 15
▼ + stars: | 2023-10-03 | by ( ) www.reuters.com time to read: +1 min

Staff members install a sign reading "Nipah isolation ward, entry strictly prohibited" at a hospital where a ward is being prepared for suspected Nipah virus patients in Kozhikode district, Kerala, India, September 12, 2023. REUTERS/Stringer/File Photo Acquire Licensing RightsOct 3 (Reuters) - No fresh cases of the deadly Nipah virus have been detected since Sept. 15 in India's southern state of Kerala, the World Health Organization (WHO) said on Tuesday. All infected cases were males aged between nine to 45 years and were reported within the Kozhikode district of Kerala, the WHO said, citing India's Ministry of Health and Family Welfare. Currently, there is no vaccine for Nipah, which spreads through contact with infected animals such as bats and pigs. Reporting by Sriparna Roy in Bengaluru; Editing by Anil D'SilvaOur Standards: The Thomson Reuters Trust Principles.

Persons: Stringer, Sriparna Roy, Anil D'Silva Organizations: REUTERS, World Health Organization, WHO, India's Ministry of Health, Family Welfare, Thomson Locations: Kozhikode district, Kerala, India, India's, Kozhikode, Bengaluru

A vial labelled "Novavax COVID-19 Vaccine" is seen in this illustration taken January 16, 2022. The Maryland-based company, whose COVID vaccine is its lone marketed product, has adopted cost-cutting measures and is counting on commercial sales of its updated shot to help it stay afloat. The CDC's Advisory Committee on Immunization Practices (ACIP) will not meet again to discuss the Novavax shot, a spokesperson said. Novavax's original COVID shot received U.S. authorization in July 2022, long after Pfizer and Moderna vaccines were in use. All three of the updated shots target the XBB.1.5 variant of the coronavirus.

Persons: Dado Ruvic, BioNTech, COVID, John Jacobs, Jacobs, Sriparna Roy, Bill Berkrot Organizations: REUTERS, U.S . Food, Drug Administration, U.S . Centers for Disease Control, Prevention, Pfizer Inc, Moderna, FDA, Pfizer, Moderna's, Thomson Locations: U.S, Maryland, Bengaluru

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. The concerns over the limited use of the drug, however, dragged the shares down to settle 8% lower. That makes the label narrower than that in Europe, which allows use in all adults with late-onset Pompe disease. At least one analyst said the drug's label, which restricts its use only to switch patients, weighed on the drugmaker's shares. Amicus said it would launch the therapy immediately in the U.S. with a list price of around $650,000 for a patient weighing about 70 kilograms.

Persons: Andrew Kelly, Needham, Gil Blum, Sriparna Roy, Shinjini Ganguli, Sriraj, Shweta Agarwal Organizations: Food and Drug Administration, FDA, REUTERS, Amicus Therapeutics, U.S . Food, Sanofi, Amicus, Thomson Locations: White Oak , Maryland, U.S, Europe, Sanofi, Bengaluru

☆ US CDC panel weighs use of Pfizer's maternal RSV vaccine to protect infants
▼ + stars: | 2023-09-22 | by ( ) www.reuters.com time to read: +2 min

[1/3] A child suffering from an RSV infection at the pediatric intensive care unit at the Asklepios Clinic in Sankt Augustin, Germany, December, 6, 2022. RSV is a common respiratory virus that usually causes mild, cold-like symptoms but can also lead to serious illness and hospitalization. It is typically a seasonal illness, starting in the autumn and peaking in the winter in most of the U.S., according to the CDC. An estimated 58,000 to 80,000 children below the age of five years are hospitalized every year due to RSV infection in the U.S., according to government data. However, the agency said the difference did not appear to be statistically significant, thus might have been due to chance.

Persons: Benjamin Westhoff, Sriparna Roy, Bill Berkrot Organizations: Asklepios, REUTERS, Pfizer, GSK, U.S . Centers for Disease Control, Prevention, U.S . Food, Drug Administration, CDC, FDA, Thomson Locations: Sankt Augustin, Germany, U.S, Bengaluru

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. The rejection and request for additional testing sharply contrasts the backing from the U.S. Food and Drug Administration's (FDA) independent experts for the spray, neffy, in May. EpiPen-maker Viatris (VTRS.O) had in June petitioned the FDA to require that ARS conduct more trials that closely mimic real-world conditions. It did not test neffy in anaphylaxis, a severe, life-threatening allergic reaction, due to ethical concerns. ARS expects to re-submit its application in the first half of 2024, with an FDA decision likely in the second half.

Persons: Andrew Kelly, William Blair, Tim Lugo, Stacey Saiontz, anaphylaxis, James Tarbox, Christy Santhosh, Sriparna Roy, Jahnavi, Varun Organizations: Food and Drug Administration, FDA, REUTERS, ARS Pharmaceuticals, U.S . Food, Pharma, Regulators, ARS, Texas Tech University Health Sciences Center, Thomson Locations: White Oak , Maryland, U.S, anaphylaxis, Bengaluru

☆ COVID vaccine manufacturers set list price between $120-$130 per dose
▼ + stars: | 2023-09-12 | by ( ) www.reuters.com time to read: +1 min

A patient receives their coronavirus disease (COVID-19) vaccine booster during a Pfizer-BioNTech vaccination clinic in Southfield, Michigan, U.S., September 29, 2021. REUTERS/Emily Elconin/File photo Acquire Licensing RightsCompanies BioNTech SE FollowModerna Inc FollowNovavax Inc Follow Show more companiesSept 12 (Reuters) - U.S. COVID vaccine manufacturers set list prices for their shots between $120 and $130 per dose, company executives said at an advisory panel meeting of U.S. Centers for Disease Control and Prevention on Tuesday. Pfizer (PFE.N) and German partner BioNTech (22UAy.DE) set the list price at $120 per dose, while Moderna (MRNA.O) said the list price for its shot is $129 per dose, for their respective COVID vaccines. Novavax (NVAX.O) said the list price for its COVID vaccine was $130 per dose. Reporting by Bhanvi Satija and Sriparna Roy in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles.

Persons: Emily Elconin, BioNTech, Bhanvi Satija, Sriparna Roy, Shounak Dasgupta Organizations: Pfizer, REUTERS, U.S . Centers for Disease Control, Moderna, Thomson Locations: Southfield , Michigan, U.S, Bengaluru

☆ US FDA authorizes Pfizer-BioNTech and Moderna's updated COVID shots
▼ + stars: | 2023-09-11 | by ( ) www.reuters.com time to read: +2 min

[1/3] Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. A third shot, made by Novavax (NVAX.O), is still under review by the FDA. But obviously that requires that FDA have decided the data supports it," said Jesse Goodman, a professor at Georgetown and former FDA chief scientist. Moderna and Pfizer, which is partnered with German biotech firm BioNTech SE (22UAy.DE), said the updated vaccines were expected to be available the United States in the coming days. An endorsement by CDC Director Mandy Cohen, expected shortly, should clear the way for the new shots.

Persons: Andrew Kelly, Novavax, Jesse Goodman, —, Mandy Cohen, Cohen, Sriparna Roy, Mariam Sunny, Michael Erman, Shinjini Organizations: Food and Drug Administration, FDA, REUTERS, Pfizer, Moderna, U.S . Food, Drug Administration, for Disease Control, Prevention, Georgetown, EG, CDC, Thomson Locations: White Oak , Maryland, U.S, United States, Bengaluru, New York

A general view of the drug product manufacturing laboratory in biologics and sterile injectables, Catalent, in Brussels, Belgium June 27, 2023. Catalent named three pharma industry executives and a senior Elliott executive to its board and said John Greisch, who has served on the board since 2018, will become executive chairman. Elliott, whose stake in Catalent became public last month, has been engaging with the company behind the scenes for months. Two of the directors were picked by Elliott, while two were mutually agreed by Elliott and Catalent. Catalent is also forming a new strategic and operational review committee which Greisch will chair.

Persons: Yves Herman, Elliott, Catalent, Alessandro Maselli, John Greisch, Max, William Blair, Maselli, Steven Barg, Goldman Sachs, Frank D'Amelio, Stephanie Okey, Michelle Ryan, Greisch, Merck KGaA, Svea Herbst, Bayliss, Maggie Fick, Sriparna Roy, Shinjini Ganguli, Catherine Evans, Mike Harrison Organizations: REUTERS, Catalent Inc, Elliott Investment Management, Reuters, Novo, pharma, U.S . Food, Drug Administration, Pfizer, Johnson, Catalent, Svea, Thomson Locations: Brussels, Belgium, ., Danish, Novo, United States, Catalent, GLP, Boston, London, Bengaluru

[1/2] A pharmacist holds a bottle of the drug Eliquis, sold by Bristol Myers Sqibb and Pfizer at a pharmacy in Provo, Utah, U.S. January 9, 2020. REUTERS/George Frey/File Photo Acquire Licensing RightsAug 29 (Reuters) - The U.S. government on Tuesday selected the first 10 drugs, including the big-selling blood thinner Eliquis from Bristol Myers Squibb (BMY.N) and Pfizer (PFE.N) , that will be subject to the first-ever Medicare price negotiations, part of President Joe Biden’s Inflation Reduction Act (IRA) that drugmakers and industry groups have challenged in court. At least eight lawsuits were filed between June and late August seeking to block the price negotiation, arguing that the law and forced price cuts would violate various amendments to the U.S. constitution. The following are key details of the lawsuits:Reporting by Manas Mishra and Sriparna Roy in Bengaluru; Editing by Bill BerkrotOur Standards: The Thomson Reuters Trust Principles.

Persons: Bristol Myers Sqibb, George Frey, Joe Biden’s, Manas Mishra, Sriparna Roy, Bill Berkrot Organizations: Bristol, Pfizer, REUTERS, U.S, Bristol Myers Squibb, Thomson Locations: Provo , Utah, U.S, Bengaluru

Search resuls for: "Sriparna Roy"

25 mentions found